A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

This is a Phase 1, open-label study to evaluate the safety, tolerability, and
pharmacokinetics of TAS-102 in patients with advanced solid tumors with varying degrees of
hepatic impairment. The study is conducted in 2 parts: the Pharmacokinetic Part (Cycle 1)
and the Extension Part (Cycles 2 and beyond). Patients may continue to receive treatment
with TAS-102 during the study extension part only after completion of the Pharmacokinetic
Part.

Inclusion

1. Has provided written informed consent

2. Has advanced solid tumors (excluding breast cancer)

3. Has normal hepatic function, mild, moderate, or severe hepatic impairment

4. ECOG performance status of ≤2

5. Is able to take medications orally

6. Has adequate organ function

7. Women of childbearing potential must have a negative pregnancy test and must agree to
adequate birth control if conception is possible. Males must agree to adequate birth
control.

Exclusion

1. Certain serious illnesses or medical condition(s)

2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,
extended field radiation, received investigational agent, shunt in the liver within
the specified time frames prior to study drug administration

3. Has received TAS-102

4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
prior therapies

5. Is a pregnant or lactating female